Amryt announces senior management appointment
Irish-listed Amryt Pharma, a biopharmaceutical company focused on best-in-class treatments for rare and orphan diseases, has announced the appointment of Kieran Rooney, Ph.D., as vice president of strategic alliances and licensing.
Dr. Rooney has over 25 years of experience in the biopharmaceutical industry, with significant expertise in business development and commercial strategy.
Before joining Amryt, he founded Halo BioConsulting, a global healthcare advisory services firm focusing on business alliances and management consulting.
Prior to that, Dr. Rooney worked as a consultant for the UK Government and held business development roles at companies including Smith & Nephew, F2G Limited, Pharsight Corporation, and MDS Pharma Services.
Commenting on the announcement, Joe Wiley, CEO of Amryt said he was pleased to welcome Dr. Rooney to the team.
"Kieran will be responsible for assessing new acquisition and in-licencing opportunities as we continue to execute our strategy to acquire, develop and commercialise products to enhance the lives of patients with rare and orphan diseases" Mr Wiley said.
Dr. Rooney holds a Ph.D. in Neuropharmacology from the University of Wales, Cardiff and is a Member of the Royal Pharmaceutical Society of Great Britain.
Earlier this year the company announced that a long-term study into the treatment of a rare, genetic, and life-threatening disease, Homozygous Familial Hypercholesterolaemia, using Lojuxta has shown highly positive results.
Homozygous Familial Hypercholesterolaemia ("HoFH") impairs the body's ability to remove bad cholesterol from the blood.